Drug intelligence / Profile preview

mRNA-1982

Development stage: Phase 2
Lead developer: Moderna
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

mRNA-1982 is an investigational monovalent mRNA vaccine developed by Moderna for the prevention of Lyme disease. It is designed to elicit antibodies specifically against *Borrelia burgdorferi*, the bacterium responsible for nearly all cases of Lyme disease in the United States. The vaccine uses messenger RNA (mRNA) technology to instruct cells to produce antigens from *B. burgdorferi*, thereby stimulating an immune response that can protect against infection. As of early 2025, mRNA-1982 is being evaluated in Phase 2 clinical trials for safety and immunogenicity in healthy adults[1][4][7].

Targets

OspA (Outer surface protein A)

Beyond the preview

Go deeper on mRNA-1982.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mRNA-1982.

Explore the full profile